Plantier J, Forrey A W, O'Neill M A, Blair A D, Christopher T G, Cutler R E
J Infect Dis. 1976 Nov;134 SUPPL:S323-30. doi: 10.1093/infdis/135.supplement_2.s323.
The acetylating radioenzymatic assay was used for determination of levels of amikacin in serum and urine. Because of an inhibitor present in various amounts in urine, assay of amikacin in urine by this method requires added internal standards and thus is less precise than the assay in serum. Determination of the rate of plasma clearance, half-life, and volume of distribution of amikacin in 10 patients with normal renal function, four patients undergoing dialysis, and five patients with end-stage renal diseases have shown a relation of half-life (t1/2 in hr) to rate of clearance of serum creatinine (Cer) of t1/2 = 3 X Cer, the same relation as found for kanamycin and gentamicin. The apparent steady-state volume of distribution of amikacin in patients with diminished renal function is slightly, but not significantly, larger than that in normal patients; the values were 0.28 +/- 0.10 and 0.21 +/- 0.10, respectively. In normal patients, 87% of the drug is excreted by the kidney.
采用乙酰化放射酶法测定血清和尿液中阿米卡星的水平。由于尿液中存在含量各异的抑制剂，用该方法测定尿液中的阿米卡星需要添加内标，因此其准确性低于血清检测。对10名肾功能正常的患者、4名正在接受透析的患者以及5名终末期肾病患者的血浆清除率、半衰期和分布容积进行测定后发现，半衰期（t1/2，单位为小时）与血清肌酐清除率（Cer）的关系为t1/2 = 3×Cer，这与卡那霉素和庆大霉素的关系相同。肾功能减退患者中阿米卡星的表观稳态分布容积略大于正常患者，但差异不显著；数值分别为0.28±0.10和0.21±0.10。在正常患者中，87%的药物通过肾脏排泄。
